MCID: ACT008
MIFTS: 51

Actinic Keratosis

Categories: Skin diseases, Cancer diseases

Aliases & Classifications for Actinic Keratosis

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 12 52 14 69
Senile Hyperkeratosis 12
Seborrheic Keratosis 69
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 42
Solar Keratosis 12

Classifications:



Summaries for Actinic Keratosis

MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to actinic cheilitis and keratosis. An important gene associated with Actinic Keratosis is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Pathways in cancer and Mitotic G1-G1/S phases. The drugs Picato gel and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and growth/size/body region

Wikipedia : 72 Actinic keratosis (AK) is a pre-cancerous patch of thick, scaly, or crusty skin. These growths are more... more...

Related Diseases for Actinic Keratosis

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 actinic cheilitis 11.1
2 keratosis 11.1
3 cervical adenoid cystic carcinoma 10.9 CDKN2A TP53
4 split hand split foot nystagmus 10.8 CDKN2A TP53
5 tendon sheath lipoma 10.8 PTGS2 TP53
6 anal squamous cell carcinoma 10.8 CDKN2A TP53
7 rectum squamous cell carcinoma 10.8 CDKN2A TP53
8 breast myoepitheliosis 10.8 CDKN2A TP53
9 ritter's disease 10.7 CDKN2A TP53
10 brachial amelia, forebrain defects and facial clefts 10.7 CDKN2A PTGS2
11 spastic paraplegia 3a, autosomal dominant 10.7 MMP14 MMP2
12 nephrotic syndrome, type 12 10.7 MMP14 MMP2
13 coccidiosis 10.7 CDKN2A TP53
14 intrahepatic bile duct adenoma 10.7 KRT20 TP53
15 extrahepatic bile duct adenoma 10.7 KRT20 TP53
16 adenocarcinoma in situ 10.7 CDKN2A TP53
17 duodenum cancer 10.7 CDKN2A TP53
18 chronic neutrophilic leukemia 10.7 CDKN2A KRT20
19 vulva squamous cell carcinoma 10.7 CDKN2A KRT20
20 squamous cell carcinoma 10.7
21 penis paget's disease 10.6 CDKN2A TP53
22 villous adenocarcinoma 10.6 CDKN2A PTGS2 TP53
23 esophagus squamous cell carcinoma 10.6 CDKN2A PTGS2 TP53
24 rare endometriosis 10.6 CDKN2A MMP2 TP53
25 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 10.6 CDKN2A PTGS2 TP53
26 gastrointestinal neuroendocrine tumor 10.6 CDKN2A PTGS2 TP53
27 tracheal disease 10.6 CDKN2A MMP2 TP53
28 hodgkin's lymphoma, mixed cellularity 10.6 CDKN2A MMP2 TP53
29 myotonia congenita 10.6 CDKN2A KRT20
30 pancreatoblastoma 10.6 CDKN2A TNC TP53
31 trachea squamous cell carcinoma 10.6 CDKN2A MMP2 TP53
32 active vestibular meniere's disease 10.6 CDKN2A PTGS2
33 breast pericanalicular fibroadenoma 10.6 KRT20 TP53
34 estrogen-receptor negative breast cancer 10.6 CDKN2A PTGS2 TP53
35 leucocyte adhesion defect 10.6 MC1R MMP2
36 leiomyoma cutis 10.6 CDKN2A PCNA TP53
37 vipoma 10.6 KRT17 KRT20
38 bardet-biedl syndrome 10.6 CDKN2A MMP2 TP53
39 bone giant cell tumor 10.6 KRT20 TP63
40 orbital lymphoma 10.6 CDKN2A PCNA TP53
41 gastric adenocarcinoma 10.6 KRT20 PCNA
42 phalanx chondroma 10.6 CDKN2A TP53
43 skin amelanotic melanoma 10.6 CDKN2A MMP14 MMP2
44 amelogenesis imperfecta local hypoplastic 10.6 CDKN2A TP63
45 tenosynovitis of foot and ankle 10.6 MMP14 MMP2 TP53
46 retinal detachment 10.6 CDKN2A KRT20 TP53
47 pigmented basal cell carcinoma 10.6 KRT17 KRT20
48 follicular basal cell carcinoma 10.6 KRT17 KRT20
49 hepatic flexure cancer 10.6 CDKN2A MMP2 TP53
50 acute porphyria 10.6 CDKN2A PTGS2 TP53

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis

Symptoms & Phenotypes for Actinic Keratosis

GenomeRNAi Phenotypes related to Actinic Keratosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CDKN2A CFLAR MCM2 PCNA TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 CDKN2A CFLAR MCM2 PCNA TP53 TP63

MGI Mouse Phenotypes related to Actinic Keratosis:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 TP63 CDKN2A CFLAR KRT17 LUM MC1R
2 cellular MP:0005384 10.26 CDKN2A CFLAR KRT17 LUM MC1R MCM2
3 behavior/neurological MP:0005386 10.23 PTGS2 TNC TP53 TP63 CDKN2A LUM
4 immune system MP:0005387 10.2 CDKN2A CFLAR LUM MC1R MCM2 MMP14
5 hematopoietic system MP:0005397 10.18 CDKN2A CFLAR LUM MC1R MCM2 MMP14
6 cardiovascular system MP:0005385 10.17 CDKN2A CFLAR LUM MMP14 MMP2 PTGS2
7 digestive/alimentary MP:0005381 10.14 CDKN2A KRT17 LUM MCM2 MMP14 PTGS2
8 endocrine/exocrine gland MP:0005379 10.11 PTGS2 TP53 TP63 CDKN2A CFLAR MCM2
9 mortality/aging MP:0010768 10.1 CDKN2A CFLAR KRT17 MCM2 MMP14 MMP2
10 integument MP:0010771 10.09 CDKN2A KRT17 LUM MC1R MCM2 MMP14
11 embryo MP:0005380 10.07 CDKN2A CFLAR MCM2 MMP14 PTGS2 TP53
12 craniofacial MP:0005382 10.02 KRT17 MC1R MMP14 MMP2 TP53 TP63
13 muscle MP:0005369 10.02 CDKN2A CFLAR LUM MCM2 MMP14 MMP2
14 no phenotypic analysis MP:0003012 9.91 CDKN2A KRT17 MC1R MMP14 PCNA PTGS2
15 neoplasm MP:0002006 9.87 CDKN2A MC1R MCM2 MMP2 PTGS2 TP53
16 pigmentation MP:0001186 9.55 CDKN2A KRT17 MC1R MCM2 TP53
17 respiratory system MP:0005388 9.5 CDKN2A MCM2 MMP14 MMP2 PTGS2 TP53
18 vision/eye MP:0005391 9.17 CDKN2A LUM MMP14 MMP2 PTGS2 TP53

Drugs & Therapeutics for Actinic Keratosis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Picato gel 17 INGENOL MEBUTATE LEO Pharma January 2012

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
2
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1 51-21-8 3385
4
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1 15307-86-5 3033
5
Alginic acid Approved, Experimental Phase 4 9005-32-7
6
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
8
Ethanol Approved Phase 4,Phase 2 64-17-5 702
9
Bezafibrate Approved Phase 4 41859-67-0 39042
10
Petrolatum Approved Phase 4,Phase 2,Early Phase 1 8009-03-8
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
12
Salicylic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 69-72-7 338
13
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
14
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
15
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
16
Menthol Approved Phase 4 2216-51-5 16666
17
Azathioprine Approved Phase 4 446-86-6 2265
18
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
19
Mycophenolic acid Approved Phase 4 24280-93-1 446541
20
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
21
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
22
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 1406-16-2
24 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
25 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
26 interferons Phase 4,Phase 3,Phase 2,Phase 1
27 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Protective Agents Phase 4,Phase 3,Phase 2
29 Radiation-Protective Agents Phase 4,Phase 2
30 Sunscreening Agents Phase 4,Phase 3,Phase 2
31 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1
32 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
34 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
38 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
41 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Retinol palmitate Phase 4,Phase 3,Phase 2
45 Viscosupplements Phase 4
46 Bone Density Conservation Agents Phase 4,Phase 1,Early Phase 1
47 Ergocalciferols Phase 4,Phase 1
48 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Vitamins Phase 4,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 331)

id Name Status NCT ID Phase Drugs
1 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
2 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
3 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
4 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
5 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
6 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
7 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
8 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
9 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
10 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
11 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
12 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
13 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
14 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine
15 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
16 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
17 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
18 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
19 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
20 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
21 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
22 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
23 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
24 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Recruiting NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
25 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Recruiting NCT02990221 Phase 4 Ingenol mebutate
26 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
27 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
28 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Recruiting NCT02866695 Phase 4 ingenol mebutate gel 0.015%
29 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Active, not recruiting NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
30 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
31 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
32 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
33 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
34 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
35 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
36 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
37 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
38 Actinic Keratoses Treatment With Metvix® in Combination With Light Unknown status NCT02373371 Phase 3 Metvix®
39 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
40 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
41 A Study of the Clinicopathologic Behaviour of the Different Types of Unsafe Chronic Otitis Media Unknown status NCT00270660 Phase 3
42 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
43 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00742391 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
44 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00942604 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
45 Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment Completed NCT01459393 Phase 3 5-ALA Photodynamic Therapy;Cryotherapy with liquid nitrogen
46 A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Completed NCT00915551 Phase 3 PEP005 (Ingenol Mebutate) gel, 0.015%;Vehicle Gel
47 A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Completed NCT00916006 Phase 3 PEP005 Gel;Vehicle gel
48 Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Completed NCT00304239 Phase 3
49 Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Completed NCT00306800 Phase 3
50 Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Completed NCT02289768 Phase 3 5-fluorouracil/salicylic acid;Vehicle

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Genetic Tests for Actinic Keratosis

Anatomical Context for Actinic Keratosis

MalaCards organs/tissues related to Actinic Keratosis:

39
Skin, Testes, Kidney, T Cells, Neutrophil, Liver, Bone

Publications for Actinic Keratosis

Articles related to Actinic Keratosis:

(show top 50) (show all 557)
id Title Authors Year
1
In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire. ( 28776637 )
2017
2
CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas. ( 28267402 )
2017
3
Patient satisfaction and reported outcomes on the management of actinic keratosis. ( 28553130 )
2017
4
Predictors of actinic keratosis count in patients with multiple keratinocyte carcinomas: A cross-sectional study. ( 28088997 )
2017
5
Epithelial-to-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. ( 28796927 )
2017
6
Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not "high risk": Diagnosis, management, and clinical outcomes in a series of 115 cases. ( 27889291 )
2017
7
Field treatment of actinic keratosis on the scalp. ( 28581227 )
2017
8
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. ( 28628679 )
2017
9
Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients. ( 28658998 )
2017
10
Phasor-FLIM as a Screening Tool for the Differential Diagnosis of Actinic Keratosis, Bowen's Disease, and Basal Cell Carcinoma. ( 28661125 )
2017
11
Human papilloma virus expression in immunocompetent patients with actinic keratosis: A case series. ( 28917462 )
2017
12
A seamless Phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. ( 28078678 )
2017
13
In vivo microvascular imaging of cutaneous actinic keratosis, Bowen's disease and squamous cell carcinoma using dynamic optical coherence tomography. ( 28502083 )
2017
14
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
15
Prevalence of actinic keratosis in a French cohort of elderly people: the PROOF study. ( 28906092 )
2017
16
Actinic keratosis modelling in mice: A translational study. ( 28662116 )
2017
17
Rosettes in actinic keratosis and squamous cell carcinoma: distribution, association to other dermoscopic signs and description of the rosette pattern. ( 28707711 )
2017
18
A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity. ( 28536731 )
2017
19
New and current preventive treatment options in actinic keratosis. ( 28805940 )
2017
20
Photodynamic therapy for actinic keratosis: Is the European consensus protocol for daylight PDT superior to conventional protocol for Aktilite CL 128 PDT? ( 28756154 )
2017
21
Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face. ( 28628678 )
2017
22
A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. ( 28805092 )
2017
23
Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. ( 27785771 )
2017
24
Dermatoscopic Patterns of Nonfacial Actinic Keratosis: Characterization of Pigmented and Nonpigmented Lesions. ( 28538027 )
2017
25
Actinic keratosis. Or maybe not? ( 28556349 )
2017
26
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients - a randomized intra-individual controlled trial. ( 28796885 )
2017
27
Dermoscopy of Pigmented Actinic Keratosis of the Face: A Study of 232 Cases. ( 28705516 )
2017
28
Response to: a network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. ( 27503743 )
2016
29
Adherence to topical therapies in actinic keratosis: A literature review. ( 27161045 )
2016
30
Expression of p300 and p300/CBP associated factor (PCAF) in actinic keratosis and squamous cell carcinoma of the skin. ( 27019369 )
2016
31
Adherence to topical treatments for actinic keratosis. ( 27790670 )
2016
32
Tolerability of Ingenol Mebutate Gel, 0.05%, for Treating Patients with Actinic Keratosis on the Scalp in a Community Dermatology Practice. ( 27354884 )
2016
33
Actinic keratosis-related signs predictive of squamous cell carcinoma in renal transplant recipients: a nested case-control study. ( 27584866 )
2016
34
Histopathology and reflectance confocal microscopy features of photodamaged skin and actinic keratosis. ( 27298142 )
2016
35
Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma. ( 27519350 )
2016
36
Actinic keratosis as a marker of field cancerization in excision specimens of cutaneous malignancies. ( 27416085 )
2016
37
Efficacy of ingenol mebutate gel for actinic keratosis in patients treated by thiazide diuretics. ( 27853385 )
2016
38
A new algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma based on in vivo analysis of optical properties by high-definition optical coherence tomography. ( 27311752 )
2016
39
Electrospun poly-l-lactide scaffold for the controlled and targeted delivery of a synthetically obtained Diclofenac prodrug to treat actinic keratosis. ( 27816622 )
2016
40
Prevalence of actinic keratosis among dermatology outpatients in Spain. ( 27445129 )
2016
41
Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study. ( 27088541 )
2016
42
Defining Field Cancerization of the Skin Using Noninvasive Optical Coherence Tomography Imaging to Detect and Monitor Actinic Keratosis in Ingenol Mebutate 0.015%- Treated Patients. ( 27386042 )
2016
43
Actinic Keratosis Pathogenesis Update and New Patents. ( 27142784 )
2016
44
Actinic keratosis in China: big numbers and small percentages. ( 27206355 )
2016
45
The current role of in vivo reflectance confocal microscopy within the continuum of actinic keratosis and squamous cell carcinoma: a systematic review. ( 28007674 )
2016
46
A 9-month, randomized, assessor-blinded parallel-group study to evaluate clinical effects of a film-forming medical devices containing photolyase and sun-filters in the treatment of cancerization field in comparison with sunscreen in patients after successful PDT for Actinic Keratosis. ( 27167413 )
2016
47
Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate. ( 27513957 )
2016
48
Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolevulinic acid photodynamic therapy for the treatment of multiple actinic keratosis. ( 28012181 )
2016
49
Case of Japanese Hermansky-Pudlak syndrome patient with deeply invasive squamous cell carcinoma and multiple lesions of actinic keratosis on the face and neck. ( 27178242 )
2016
50
Correction: E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice. ( 27792794 )
2016

Variations for Actinic Keratosis

Cosmic variations for Actinic Keratosis:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM45765 TP53 skin,leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 3
2 COSM10863 TP53 skin,leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 3
3 COSM45114 TP53 skin,leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 3
4 COSM573 NRAS skin,scalp,carcinoma,squamous cell carcinoma c.38G>A p.G13D 3
5 COSM521 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.35G>A p.G12D 3
6 COSM554 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.183A>C p.Q61H 3
7 COSM499 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 3
8 COSM498 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 3
9 COSM12475 CDKN2A skin,leg,carcinoma,squamous cell carcinoma c.238C>T p.R80* 3

Expression for Actinic Keratosis

Search GEO for disease gene expression data for Actinic Keratosis.

Pathways for Actinic Keratosis

GO Terms for Actinic Keratosis

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.96 PCNA TP53
2 extracellular matrix GO:0031012 8.92 LUM MMP14 MMP2 TNC

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.65 LUM MMP14 PTGS2
2 response to oxidative stress GO:0006979 9.63 MMP14 PCNA PTGS2
3 cellular response to hypoxia GO:0071456 9.5 CFLAR PTGS2 TP53
4 intermediate filament organization GO:0045109 9.43 KRT17 KRT20
5 apoptotic process GO:0006915 9.43 CDKN2A CFLAR KRT20 MCM2 TP53 TP63
6 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.4 CFLAR TMC8
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 TP53 TP63
8 replicative senescence GO:0090399 9.26 CDKN2A TP53
9 mitotic G1 DNA damage checkpoint GO:0031571 9.16 TP53 TP63
10 cellular response to UV GO:0034644 8.92 PCNA PTGS2 TP53 TP63

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 CDKN2A CFLAR KRT17 KRT20 LUM MC1R
2 enzyme binding GO:0019899 9.46 MCM2 PCNA PTGS2 TP53
3 damaged DNA binding GO:0003684 8.8 PCNA TP53 TP63

Sources for Actinic Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....